Compare ResMed Inc. (RMD) vs Twilio Inc (TWLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Twilio Inc — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.89B), while Twilio Inc trades at $227.45 (market cap $34.69B). The key difference: ResMed Inc. and Twilio Inc are close in size by market cap, and ResMed Inc. pays a 1.19% dividend while Twilio Inc pays none. Which is the better fit depends on your goals.
| RMD | TWLO | |
|---|---|---|
Market Cap | $31.89B | $34.69B |
Sector | Health | Technology |
52-Week High | $283.28 | $255.95 |
52-Week Low | $182.82 | $100.09 |
Enterprise Value | $31.24B | $33.10B |
Dividend Yield | 1.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% amid a bearish technical signal, though it holds above key support at $218. The company reported strong Q4 2026 results with EPS of $2.95 beating estimates, and revenue grew 9% to a record $1.5 billion. However, weaker fiscal 2027 revenue guidance has pressured the stock. Fundamentals remain solid with a 26.94% net income margin and robust cash flow from operations of $1.75 billion in 2025.
The outlook is mixed; strong profitability and consistent earnings beats support upside toward the $235.70 consensus price target, but near-term sentiment is cautious due to the soft sales forecast and ongoing legal investigations. Key risks include competitive pressures and execution on guidance. Institutional buying by firms like HSBC and Canada Pension Plan provides confidence in long-term value.
Twilio (TWLO) trades at $225.89, down 3.04% today, showing strong fundamental momentum with three consecutive quarterly earnings beats and accelerating revenue growth from $3.8B in 2022 to $5.1B in 2025. The company has achieved profitability with a 20.62% net income margin in 2025, reversing previous losses, while technical indicators show a neutral stance with support at $222 and resistance at $230.
The outlook remains positive with 77% analyst buy ratings and a $266.31 consensus price target, representing 18% upside potential. Key risks include execution of AI strategy and competitive pressures in communications infrastructure, but strong free cash flow generation and strategic positioning for AI-driven customer engagement support the bullish case.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →
